Skip to main content
SpringerLink
Log in

Relationship between Methylation of FHIT and CDH13 Gene Promoter Region and Liver Cancer

  • Published:
Current Medical Science Aims and scope Submit manuscript

Summary

In order to demonstrate the relationship between methylation of fragile histidine triad (FHIT) and T-cadherin/H-cadherin (CDH13) genes and liver cancer, the methylation status of FHIT and CDH13 was detected in healthy individuals and in Mongolian and Han patients with liver cancer. The phenol-chloroform method was used to extract genomic DNA. The methylation specific polymerase chain reaction method was applied to detect the methylation status of FHIT and CDH13. The relationship between smoking and alcohol consumption and gene (FHIT and CDH13) methylation was analyzed. There was significant difference in methylation rate of FHIT (72.67%, 34.67%) and CDH13 (72.0%, 28.0%) between liver cancer patients and healthy individuals of Mongolian descent (P<0.05), as well as that of FHIT (68%, 30.67%) and CDH13 (64%, 26%) between liver cancer patients and healthy individuals of Han individuals (P<0.05). There was also a relationship between smoking and drinking and the methylation of FHIT and CDH13 (P<0.05). Thus, the methylation of FHIT and CDH13 had a relationship with liver cancer incidence. Smoking and alcohol ingestion may promote the methylation of FHIT and CDH13.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chiang JK, Chih WL, Kao YH. Effect of ultrasonography surveillance in patients with liver cancer: a population-based longitudinal study. BMJ Open, 2017, 7(6):e015936

    PubMed  PubMed Central  Google Scholar 

  2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CACancer J Clin, 2016, 66(2): 115–132

    Google Scholar 

  3. Zhang QB, Meng XT, Jia QA, et al. Herbal compound songyou yin and moderate swimming suppress growth and metastasis of liver cancer by enhancing immune function. Integr Cancer Ther, 2016, 15(3): 368–375

    CAS  PubMed  Google Scholar 

  4. Karpf AR. Epigenomic reactivation screening to identify genes silenced by DNA hypermethylation in human cancer. Curr Opin Mol Ther, 2007, 9(3): 231–241

    CAS  PubMed  Google Scholar 

  5. Huang QB, Zhang HW, Liao ZB. Carboxypeptidase A6 Promotes the Proliferation and Migration of Hepatocellular Carcinoma by Up-regulating AKT Signaling Pathway. Curr Med Sci, 2019, 39(5): 727–733

    CAS  PubMed  Google Scholar 

  6. Zhao BB, Ye ZH, Gao X, et al. Diwu Yanggan Modulates the Wnt/p-catenin Pathway and Inhibits Liver Carcinogenesis Signaling in 2-AAF/PH Model Rats. Curr Med Sci, 2019, 39(6): 913–919

    PubMed  Google Scholar 

  7. Wang Q, Pan LH, Lin L, et al. Essential Oil from Carpesium abrotanoides L. Induces Apoptosis via Activating Mitochondrial Pathway in Hepatocellular Carcinoma Cells. Curr Med Sci, 2018, 38(6): 1045–1053

    CAS  PubMed  Google Scholar 

  8. Li Q, Ding L, Jing N, et al. Folate deficiency and aberrant DNAmethylation and expression of FHIT gene were associated with cervical pathogenesis. Oncol Lett, 2018, 15(2): 1963–1972

    PubMed  Google Scholar 

  9. Druck T, Hadaczek P, Fu TB, et al. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res, 1997, 57(3): 504–512

    CAS  PubMed  Google Scholar 

  10. Sirnes S, Honne H, Ahmed D, et al. DNA methylation analyses of the connexin gene family reveal silencing of GJC1 (Connexin45) by promoter hypermethylation in colorectal cancer. Epigenetics, 2011, 6(5): 602–609

    CAS  PubMed  Google Scholar 

  11. Hibi K, Kodera Y, Ito K, et al. Methylation pattern of CDH13 gene in digestive tract cancers. Br J Cancer, 2004, 91: 1139–1142

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Lin YL, Xie PG, Ma JG. Aberrantmethylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer. Med Sci Momt, 2014, 20: 1572–1577

    CAS  Google Scholar 

  13. Ren JZ, Huo JR. Correlation between T-cadherin gene expression and aberrant methylation of T-cadherin promoter in human colon carcinoma cells. Med Oncol, 2012, 29(2): 915–918

    CAS  PubMed  Google Scholar 

  14. Widschwendter A, Ivarsson L, Blassnig A, et al. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer, 2004, 109(2): 163–166

    CAS  PubMed  Google Scholar 

  15. Yang J, Niu H, Huang Y, et al. A systematic analysis of the relationship of CDH13 promoter methylation and breast cancer risk and prognosis. PLoS One, 2016, 11(5):e0149185

    PubMed  PubMed Central  Google Scholar 

  16. Wang Y, Zhang L, Yang J, et al. CDH13 promoter methylation regulates cisplatin resistance of non-small cell lung cancer cells. Oncol Lett, 2018, 16(5): 1139–1143

    Google Scholar 

  17. Zhong YH, Peng H, Cheng HZ, et al. Quantitative assessment of the diagnostic role of CDH13 promoter methylation in lung cancer. Asian Pac J Cancer Prev, 2015, 16(3): 1139–1143

    PubMed  Google Scholar 

  18. Kochl S, Niederstatter H, Parson W. DNA extraction and quantitation of forensic samples using the phenol-chloroform method and real-time PCR. In: Carracedo A, ed. Forensic DNA Typing Protocols. Methods in Molecular Biology. Totowa, NJ, USA: Humana Press, 2005:13–29.

    Google Scholar 

  19. Szumilas M. Explaining odds ratios. J Can Acad Child Adolesc Psychiatry, 2010, 19(3): 3–227

    Google Scholar 

  20. McKillop IH, Schrum LW. Alcohol and liver cancer. Alcohol, 2005, 35(3): 195–203

    CAS  PubMed  Google Scholar 

  21. Shanmugham JR, Zavras Al, Rosner BA, et al. Alcohol-folate interactions in the risk of oral cancer in women: a prospective cohort study. Cancer Epidemiol Prev Biomarkers, 2010, 19(10): 2516–2524

    CAS  Google Scholar 

  22. Lee YCA, Cohet C, Yang YC, et al. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol, 2009, 38(6): 1497–1511

    PubMed  Google Scholar 

  23. Qi JJ, Wen J, Zhang LY, et al. Correlation between diabetes and smoking index and benign prostatic hyperplasia. Shandong Med J (Chinese), 2010, 50(39): 3–5

    Google Scholar 

  24. Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3pl4.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell, 1996, 84(4): 587–597

    CAS  PubMed  Google Scholar 

  25. Ranscht B, Dours Zimmermann MT. T-cadherin, a novel cadherin cell adhesion molecule in the nervous system lacks the conserved cytoplasmic region. Neuron, 1991, 7(3): 391–402

    CAS  PubMed  Google Scholar 

  26. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature, 2009, 462(7271): 315–322

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Zhu C, Feng X, Ye G, et al. Meta-analysis of possible role of cadherin gene methylation in evolution and prognosis of hepatocellular carcinoma with a PRISMA guideline. Medicine, 2017, 96(16):e6650

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev, 2002, 16: 6–21

    CAS  PubMed  Google Scholar 

  29. Jones PA, Buckley JD. The role of DNA methylation in cancer. Adv Cancer Res, 1990, 54: 1–23

    CAS  PubMed  Google Scholar 

  30. Su Y, Wang X, Li J, et al. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review. Drug Des Devel Ther, 2015, 2015(9): 5439–5445

    Google Scholar 

  31. Kuroki T, Trapasso F, Yendamuri S, et al. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res, 2003, 63(3): 3724–3728

    CAS  PubMed  Google Scholar 

  32. Drilon A, Sugita H, Sima CS, et al. A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers. J Thorac Oncol, 2014, 9(9): 1272–1277

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Konishi K, Watanabe Y, Shen L, et al. DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis. PLoS One, 2011, 6:e27889

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Moelans CB, de Groot JS, Pan X, et al. Clonal intratumor heterogeneity of promoter hypermethylation in breast cancer by MS-MLPA. Mod Pathol, 2014, 27: 869–874

    CAS  PubMed  Google Scholar 

  35. Tahara T, Maegawa S, Chung W, et al. Examination of whole blood DNA methylation as a potential risk marker for gastric cancer. Cancer Prev Res (Phila), 2013, 6(10): 1093–1100

    CAS  Google Scholar 

  36. Jin Z, Cheng Y, Olaru A, et al. Promoter hypermethylation of CDH13 is a common, early event inhuman esophageal adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer, 2008, 123(10) 2331–2336

    CAS  PubMed  Google Scholar 

  37. Chen F, Huang T, Ren Y, et al. Clinical significance of CDH 13 promoter methylation as a biomarker for bladder cancer: a meta-analysis. BMC Urol, 2016, 16:52

    PubMed  PubMed Central  Google Scholar 

  38. Chen YC. Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control, 2003, 14(4): 303–310

    PubMed  Google Scholar 

  39. Friedrich MG. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res, 2004, 10(22): 7457–7465

    CAS  PubMed  Google Scholar 

  40. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res, 2001, 61(24): 8659–8663

    CAS  PubMed  Google Scholar 

  41. Zhang H, Nie W, Huang F. The correlation relationship between P14ARF gene DNA methylation and primary liver cancer. Med Sci Momt, 2015, 21: 3077–3082

    CAS  Google Scholar 

  42. Hibi K, Nakayama H, Kodera Y, et al. CDH13 promoter region is specifically methylated in poorly differentiated colorectal cancer. Br J Cancer, 2004, 90: 1030–1033

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Maruyama R, Sugio K, Yoshino I, et al. Hypermethylation of FHIT as a prognostic marker in non-small cell lung carcinoma. Cancer, 2004, 100(7): 1472–1477

    CAS  PubMed  Google Scholar 

  44. Ryerson AB, Eheman CR, Altekruse SF, et al. Annual report to the nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer, 2016, 122(9): 1312–1337

    PubMed  PubMed Central  Google Scholar 

  45. Liang H, Wang J, Xiao H, et al. Estimation of cancer incidence and mortality attributable to alcohol drinking in China. BMC Pub Health, 2010, 10:730

    Google Scholar 

  46. Lin Z, Luo M, Chen X, et al. Combined detection of plasma ZIC1, HOXD10 and RUNX3 methylation is a promising strategy for early detection of gastric cancer and precancerous lesions. J Cancer, 2017, 8(6): 1038–1044

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Klootwijk R, Groenen P, Schijvenaars M, et al. Genetic variants in ZIC1, ZIC2, and ZIC3 are not major risk factors for neural tube defects in humans. Am J Med Genet A, 2004, 124(1):40–47

    Google Scholar 

  48. Shah V, Drill E, Lance-Jones C. Ectopic expression of HoxdlO in thoracic spinal segments induces motoneurons with a lumbosacral molecular profile and axon projections to the limb. DevDyn, 2004, 231(1): 1–43

    Google Scholar 

  49. Yamamoto H, Ito K, Kawai M, et al. Runx3 expression during mouse tongue and palate development. Anat Rec A Discov Mol Cell Evol Biol, 2006, 288(7): 695–699

    PubMed  Google Scholar 

  50. Zhang C, Yu W, Wang L, et al. DNA methylation analysis of the SHOX2 and RASSF1A panel m bronchoalveolar lavage fluid for lung cancer diagnosis. J Cancer, 2017, 8(17): 3585–3591

    PubMed  PubMed Central  Google Scholar 

  51. Zhu ZZ, Bao LL, Zhao K, et al. Copy Number Aberrations of Multiple Genes Identified as Prognostic Markers for Extrahepatic Metastasis-free Survival of Patients with Hepatocellular Carcinoma. Curr Med Sci, 2019, 39(5): 759–765

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010010, China

    Ao-dun Tuoya & Rui-jun Liu

  2. Department of Pharmacology of Pharmaceutical College, Inner Mongolia Medical University, Hohhot, 010010, China

    Dong-xue Wang, Meng-di Zhang, Tu-ya Bai, Xiao-li Lv & Fu-hou Chang

  3. The Center for New Drug Safety Evaluation and Research of Inner Mongolia Medical University, Hohhot, 010010, China

    Yu-shu Xing, Yu-xia Hu & Fu-hou Chang

  4. Inner Mongolia Research Center for Drug Screening, Hohhot, 010110, China

    Yu-shu Xing, Yu-xia Hu, Meng-di Zhang, Tu-ya Bai, Xiao-li Lv, Jun Li & Fu-hou Chang

Authors
  1. Ao-dun Tuoya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dong-xue Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yu-shu Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rui-jun Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu-xia Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Meng-di Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tu-ya Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiao-li Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Fu-hou Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fu-hou Chang.

Ethics declarations

The authors declare that they have no conflict of interest. All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Inner Mongolia Medical University and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Additional information

This work was supported by grants from the Major Scientific Project of the Affiliated Hospital of Inner Mongolia Medical University (No. NYFY ZD009) and National Natural Science Foundation of China (No. 81760676).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tuoya, Ad., Wang, Dx., Xing, Ys. et al. Relationship between Methylation of FHIT and CDH13 Gene Promoter Region and Liver Cancer. CURR MED SCI 40, 502–509 (2020). https://doi.org/10.1007/s11596-020-2202-4

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-020-2202-4

Keywords

Search

Navigation